Anti-CD38 antibodies or antibody variants have been shown to provide therapeutics for the treatment of CD38-positive hematological malignancies.3, 4, 5, 6, 7 Introduction of the antibody against CD38
-
Anti-CD38 antibodies or antibody variants have been shown to provide therapeutics for the treatment of CD38-positive hematological malignancies.3, 4, 5, 6, 7 Introduction of the antibody against CD38 may, however, raise concerns of side effects such as an infusion reaction and pharmacological phenomena associated with the long half-life of the antibody. Although antibodies against CD38 have been administered to patients with myeloma or B-cell lymphoma, there has been no report of adverse effects.7, 8 Indeed, daratumumab, a novel therapeutic human CD38 antibody and humanized monoclonal CD38 antibody (SAR650984) (http://clinicaltrialsfeeds.org
/clinical-trials/show/NCT01084252), is currently in clinical trials. This therapeutic option could be ready for use anytime without manipulation of cells and may be useful for most myeloma patients.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind